Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Daito Pharmaceutical Co., Ltd. ( (JP:4577) ) is now available.
Daito Pharmaceutical Co., Ltd. has revised its earnings forecast for the fiscal year ending May 31, 2025, due to lower than expected sales of high-value products and increased costs. Despite strong net sales, the company anticipates a decrease in operating, ordinary, and attributable profits, citing factors such as inventory valuation losses, higher outsourcing expenses, and increased R&D costs.
More about Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co., Ltd. operates in the pharmaceutical industry, focusing on the development and production of pharmaceutical products. The company is listed on the Prime Market of the Tokyo Stock Exchange and is known for its efforts in producing both high-value and lower-margin pharmaceutical products.
YTD Price Performance: 1.96%
Average Trading Volume: 34,705
Technical Sentiment Signal: Hold
Current Market Cap: Yen32.7B
For detailed information about 4577 stock, go to TipRanks’ Stock Analysis page.